Aptevo Therapeutics (APVO) Cash from Operations (2016 - 2023)
Historic Cash from Operations for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$6.2 million.
- Aptevo Therapeutics' Cash from Operations rose 951.28% to -$6.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$12.4 million, marking a year-over-year increase of 3452.51%. This contributed to the annual value of -$11.7 million for FY2023, which is 4420.13% up from last year.
- As of Q3 2023, Aptevo Therapeutics' Cash from Operations stood at -$6.2 million, which was up 951.28% from -$4.8 million recorded in Q2 2023.
- Over the past 5 years, Aptevo Therapeutics' Cash from Operations peaked at $4.6 million during Q1 2023, and registered a low of -$15.9 million during Q2 2019.
- For the 5-year period, Aptevo Therapeutics' Cash from Operations averaged around -$6.4 million, with its median value being -$5.9 million (2022).
- The largest annual percentage gain for Aptevo Therapeutics' Cash from Operations in the last 5 years was 18923.2% (2023), contrasted with its biggest fall of 5644.95% (2023).
- Quarter analysis of 5 years shows Aptevo Therapeutics' Cash from Operations stood at -$5.1 million in 2019, then fell by 20.06% to -$6.1 million in 2020, then surged by 36.63% to -$3.9 million in 2021, then tumbled by 53.07% to -$5.9 million in 2022, then decreased by 5.07% to -$6.2 million in 2023.
- Its Cash from Operations was -$6.2 million in Q3 2023, compared to -$4.8 million in Q2 2023 and $4.6 million in Q1 2023.